Nyxoah Reports Strong Financial Results for 2024

Nyxoah SA has released its financial and operating results for the fourth quarter and full year 2024. The company, which focuses on innovative treatments for Obstructive Sleep Apnea, posted a revenue of €1.3 million for Q4 and €4.5 million for the year, excluding deferred revenue. The gross margin for Q4 was an impressive 73%, and cash and financial assets increased significantly to €85.6 million by year-end.

The year 2024 was transformative, marked by the completion of the FDA PMA submission for Genio and significant expansion in the U.S. market, with a full commercial team now in place. This positions Nyxoah for a potential U.S. launch in the first quarter of 2025, pending FDA approval.

Despite an operating loss of €58.8 million for the year, driven by increased R&D and commercialization activities, the company remains optimistic about future opportunities, believing in an FDA approval soon.